News for #Investors and #Media

We’ve announced our Q1 2024 results. Review our key highlights. For more insights, visit us at gsk.to/44kqCSf. $GSK

News for #Investors and #Media

Explore our Q1 2024 figures at a glance. gsk.to/4aUgYZ5. $GSK

#Investors : Join GSK’s CEO Emma Walmsley and other members of our leadership team for our Q1 2024 live results webcast at 12:00 BST, 07:00 EDT. $GSK

News for #Investors and #Media

Hear our CEO Emma Walmsley talk about our strong Q1 performance and learn more about our upgraded outlooks for the year.

For more, see gsk.to/3wgznQu
$GSK #NEWS #Q1Results

#Investors and #MediaPlease read our cautionary statement regarding forward-looking statements and the definitions and reconciliations for non-IFRS measures for our Q1 2024 results. CER% represents constant exchange rates. £% or AER% represents actual exchange rates. $GSK For…

We’re announcing our Q1 2024 results tomorrow at 0700 BST, 0200 EDT. $GSK

As people’s immune systems weaken with age, the burden of vaccine-preventable diseases rises. That’s what motivates us to work towards making adult immunisation the standard of care across the globe. #WIW2024 gsk.me/3JI28Jc

Did you know there are an estimated 82 million new gonorrhoea cases globally each year?

Go Behind the Science to learn more about disease prevention 👇 gsk.me/3JDJOkr

Nine projects have been funded through #ProjectAfricaGRADIENT , a collaboration between GSK, Novartis and SAMRC. Among them, Dr. Tekete and Dr. Ouédraogo are leading two important studies, looking at the impact of genetic diversity on malaria treatment #ZeroMalaria

Discover how we are leading the fight against #infectiousdiseases . Our ground-breaking research and development efforts are aimed at protecting communities worldwide. Learn more 👇

#Vaccination plays a crucial role in adult health and productivity. A recent report from Office of Health Economics highlights the investment case for #adultvaccination , demonstrating its broader societal returns beyond individual health benefits.

Today, Liberia introduces RTS,S into its routine immunisation programme. To support this, our partner Last Mile Health is supporting the training of community health workers on delivering malaria vaccines as part of routine vaccination protocols in Liberia #WorldMalariaDay

Our £1bn investment in global health R&D over 10 yrs will help get ahead of #malaria in lower income countries. From the world’s 1st malaria vaccine to novel antimalarials we support the global elimination of malaria by helping improve prevention and treatment. #WorldMalariaDay

Investing in adult vaccination programmes plays a crucial role in protecting lives, healthcare systems and economies. The new report from Office of Health Economics evidences the Socio-Economic Value of Adult Immunisation Programmes. Check it out 👇

For the past two years, 100% of our Phase III clinical trials have had diversity plans to reflect the people most impacted by a particular disease. Find out more: gsk.to/4aNG1Nk

#News for #Investors and #Media : Our application for a potential expanded indication for our immuno-oncology therapy has been accepted by the U.S. FDA with Priority Review status. Learn more here: gsk.to/3xPNPzv

Today Save the Children UK is launching a new 'Immunisation Accelerator' to find innovations that address the barriers that exist for children receiving vaccinations. Here's Save the Children’s Dr Tewodros Gebremichael to explain more 👇 gsk.to/44abLtu

Margaret’s family has been deeply affected #malaria , but thanks to the support of Gaudenciah, a community health promoter trained by Amref Health Africa through our partnership, she is now able to access the healthcare she needs. #WorldMalariaDay gsk.to/3xJRKOj

#News for #investors and #media : Today we have announced phase III data in uncomplicated urogenital gonorrhoea (GC).
Find out more gsk.to/4aAlU5a

For #investors and #media : Today we announced new positive long-term follow-up trial data in shingles.
Find out more: gsk.to/4aXTRvY